undamentalytics Newsletter
Sign in

Dolsten Mikael: insider trades

Officer, Director at 2 companies we cover. No open-market purchases and 16 sales not made under a pre-set plan, reported from March 8, 2013 to September 9, 2026.

What happened after Dolsten Mikael’s sales?

After their sales, the shares moved −4.6% against the index over 12 months on average (a negative figure means selling was the right call); 69% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 15 −3.6% −1.5% 60% 12 −1.68 0.12 No reliable evidence
Sales, 12 months after the report 13 −4.6% −7.0% 69% 10 −1.76 0.11 No reliable evidence
Sales, 12 months after the trade 13 −5.1% −6.3% 69% 10 −1.90 0.090 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Pfizer PFE President R&D013March 8, 2013May 12, 2022
Agilent Technologies A —03December 3, 2025September 9, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
September 9, 2026September 4, 2026 A Sale $95,975 not yetnot yetnot yet
June 2, 2026May 29, 2026 A Sale $216,672 +8.7%not yetnot yet
December 3, 2025December 1, 2025 A Sale $389,506 −20.6%not yetnot yet
May 12, 2022May 11, 2022 PFE Sale $3,151,547 −6.8%−27.0%−27.6%
November 15, 2021November 11, 2021 PFE Sale $3,000,647 +5.4%+14.5%+10.7%
May 19, 2020May 18, 2020 PFE Sale $3,602,681 −11.4%−25.1%−26.4%
March 5, 2019March 1, 2019 PFE Sale $6,513,145 −0.1%−23.1%−28.8%
March 12, 2018March 9, 2018 PFE Sale $2,550,394 −1.5%+12.5%+15.4%
March 5, 2018March 2, 2018 PFE Sale $501,398 +1.3%+16.7%+17.8%
February 28, 2018February 27, 2018 PFE Sale $2,392,313 +0.2%+18.8%+18.5%
March 3, 2017March 1, 2017 PFE Sale $1,068,924 −8.0%−8.6%−6.3%
March 1, 2017February 27, 2017 PFE Sale $2,016,244 −6.9%−7.0%−6.5%
May 5, 2016May 4, 2016 PFE Sale $2,261,564 +0.8%−15.5%−14.9%
March 6, 2015March 5, 2015 PFE Sale $2,009,152 +0.2%−7.9%−8.0%
March 5, 2014March 4, 2014 PFE Sale $1,165,929 −11.3%−4.0%−4.5%
March 8, 2013March 6, 2013 PFE Sale $859,798 −4.8%−3.9%−5.0%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Dolsten Mikael traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.